Spikevax — The FDA granted full approval to Moderna’s COVID-19 vaccine, marketed under the brand name Spikevax, for adults Jan. 31.
Vabysmo — On Jan. 28, the FDA approved Roche’s faricimab-svoa, which goes by the brand name Vabysmo, to treat neovascular (wet) aged-related macular degeneration and diabetic macular edema, two leading causes of vision loss.
Kimmtrak — Tebentafusp-tebn, which goes by the brand name Kimmtrak, was approved Jan. 25 to treat unresectable or metastatic uveal melanoma.
Cibinqo — The FDA on Jan. 14 approved Pfizer’s abrocitinib, which goes by the brand name Cibinqo, for adults with moderate to severe atopic dermatitis, or eczema.
Quviviq — Daridorexant, which goes by the brand name Quviviq, was approved on Jan. 7 to treat adults with insomnia.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
